Raymond James on Eupraxia Pharmaceuticals (EPRX): 'We See an Attractive Setup for 2026 Into Ph2b RESOLVE EoE Data'
Tweet Send to a Friend
Raymond James analyst Martin Auster reiterated a Strong Buy rating and $18.00 price target on Eupraxia Pharmaceuticals (NASDAQ: EPRX).The analyst ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
